Sigilon Therapeutics Inc Quick Ratio (SGTX) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sigilon Therapeutics Inc   (NASDAQ: SGTX)

Sigilon Therapeutics Inc 's Quick Ratio

SGTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 1.38 a new company low.

Within Major Pharmaceutical Preparations industry 362 other companies have achieved higher Quick Ratio than Sigilon Therapeutics Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 1238 to 1544.

Explain Quick Ratio?
How much Cash & cash equivalents SGTX´s has?
What are SGTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGTX Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -24.23 % -21.75 % -11.16 % -25.23 % -24.93 %
Y / Y Cash & cash equivalent Change -60.43 % -45.33 % -43.56 % -44.25 % -45.69 %
Quick Ratio MRQ 1.38 1.94 2.25 2.56 2.65
SGTX's Total Ranking # 1544 # 1238 # 919 # 1244 # 1200
Seq. Current Liabilities Change -12.91 % -6.47 % 1.44 % -8.3 % -10.06 %
Seq. Cash & cash equivalent Change -38.09 % -19.04 % -11.04 % -11.27 % -14.45 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 363
Healthcare Sector # 670
Overall Market # 1544


Quick Ratio Statistics
High Average Low
5.19 2.94 1.38
(Mar 31 2021)   (Jun 30 2023)




Financial Statements
Sigilon Therapeutics Inc 's Current Liabilities $ 25 Millions Visit SGTX's Balance sheet
Sigilon Therapeutics Inc 's Cash & cash equivalent $ 35 Millions Visit SGTX's Balance sheet
Source of SGTX's Sales Visit SGTX's Sales by Geography


Cumulative Sigilon Therapeutics Inc 's Quick Ratio

SGTX's Quick Ratio for the trailling 12 Months

SGTX Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -20.76 % -21.2 % -14.68 % 7.76 % 71.58 %
Y / Y Cash & cash equivalent TTM Growth -47.44 % -44.74 % -43.93 % -42.54 % -16.26 %
Quick Ratio TTM 2.07 2.36 2.57 2.89 3.11
Total Ranking TTM # 4105 # 3959 # 2547 # 3920 # 1158
Seq. Current Liabilities TTM Growth -6.52 % -6.11 % -2.87 % -7.06 % -7.04 %
Seq. Cash & cash equivalent TTM Growth -18.23 % -13.78 % -13.67 % -13.65 % -14.02 %

Quick ratio ranking by company, industry and sector >> Back to SGTX Financial Strength Comparisons >> Go to Compare SGTX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SGTX's Current Liabilities to $25.25 millions, cumulative Quick Ratio to 2.07 below the SGTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 544 other companies have achieved higher Quick Ratio than Sigilon Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3959 to 4105.

Explain Quick Ratio?
How much Cash & cash equivalents SGTX´s has?
What are SGTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 545
Healthcare Sector # 1096
Within the Market # 4105


trailing twelve months Quick Ratio Statistics
High Average Low
3.91 2.9 2.07
(Dec 31 2021)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Gain Therapeutics inc  3.78 $ 16.193  Millions$ 4.283  Millions
Inovio Pharmaceuticals Inc   3.75 $ 194.925  Millions$ 51.932  Millions
Genelux Corporation  3.75 $ 27.140  Millions$ 7.233  Millions
Theriva Biologics inc   3.75 $ 34.248  Millions$ 9.134  Millions
Xoma Royalty Corporation  3.72 $ 31.445  Millions$ 8.455  Millions
Bioxcel Therapeutics Inc   3.67 $ 127.545  Millions$ 34.744  Millions
Corbus Pharmaceuticals Holdings Inc   3.67 $ 36.566  Millions$ 9.967  Millions
Zymeworks Inc   3.64 $ 340.089  Millions$ 93.546  Millions
Y mabs Therapeutics inc   3.63 $ 87.909  Millions$ 24.233  Millions
Alaunos Therapeutics Inc   3.63 $ 18.317  Millions$ 5.052  Millions
Travere Therapeutics Inc   3.62 $ 491.337  Millions$ 135.711  Millions
Azitra Inc   3.61 $ 6.290  Millions$ 1.741  Millions
Alterity Therapeutics Limited  3.60 $ 10.510  Millions$ 2.920  Millions
Abivax Sa  3.60 $ 282.175  Millions$ 78.447  Millions
Arcturus Therapeutics Holdings Inc   3.58 $ 323.471  Millions$ 90.345  Millions
Cue Biopharma Inc   3.55 $ 57.889  Millions$ 16.307  Millions
Apellis Pharmaceuticals Inc   3.52 $ 616.259  Millions$ 174.837  Millions
Renovorx Inc   3.50 $ 5.954  Millions$ 1.699  Millions
Quoin Pharmaceuticals Ltd   3.50 $ 15.459  Millions$ 4.414  Millions
Damora Therapeutics Inc   3.50 $ 52.124  Millions$ 14.897  Millions
Adagene Inc   3.49 $ 109.934  Millions$ 31.456  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Evoke Pharma Inc   3.45 $ 7.006  Millions$ 2.028  Millions
Trevena inc   3.44 $ 28.097  Millions$ 8.176  Millions
Galmed Pharmaceuticals Ltd   3.43 $ 9.330  Millions$ 2.723  Millions
Catalyst Pharmaceuticals Inc   3.41 $ 178.787  Millions$ 52.503  Millions
Atrium Therapeutics Inc   3.40 $ 153.880  Millions$ 45.244  Millions
Revelation Biosciences Inc   3.40 $ 15.711  Millions$ 4.624  Millions
Arvinas Inc   3.38 $ 1,038.800  Millions$ 306.900  Millions
Connect Biopharma Holdings Limited  3.36 $ 81.609  Millions$ 24.264  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.